OncoLink Cancer Treatment and Resources

Selective Bladder Preservation by Combined Modality Treatment of Invasive Bladder Cancer: 10 Year Outcome



Ryan Smith, MD
University of Pennsylvania Cancer Center
Last Modified: November 4, 2001

Presenter: W. U. Shipley
Affiliation: Massachusetts General Hospital

Background
The standard of care for muscle invasive bladder cancer is radical cystectomy +/- adjuvant chemotherapy with or without radiation. However, to improve quality of life in these patients, there is much interest in bladder-conserving therapies, using transurethral surgery and concurrent chemoradiation.

Materials and Methods

  • 190 patients with T2-4a bladder carcinoma (T2=90, T3-4a=100).
  • Twenty-seven had hydronephrosis.
  • Following TURBT, patients were treated with various induction regimens consisting of cisplatin based chemotherapy concurrent with radiation.
  • Following 40 Gy, patients were reevaluated by cytology and biopsy. Those with a CR continued to recieve boost chemoradiation to 64.8 Gy. Those with less than a CR had an immediate cystectomy.
  • Sixty percent received adjuvant MCV chemotherapy.
  • Median follow up is 6.7 years.

    Results

  • A total of 121 patients had a CR: 71% of T2 patients and 57% of T3-T4a patients.
  • Cystectomy was performed in 66 patients (35%).
  • Overall survival for the entire group was 54% at 5 years and 36% at 10 years.
  • DSS was 63% at 5 years and 59% at 10 years.
  • Disease specific survival with retention of bladder was 45% at 5 years and 43% at 10 years.
  • No patient required cystectomy due to toxicity of treatment.

    Author's Conclusions

  • Long-term OS of 36% and DSS of 59% is comparable to results with traditional therapy of radical cystectomy.
  • Given this, along with the fact that the majority have full functional use of their bladders, this bladder conserving regimen is an acceptable alternative to cystectomy in those with advanced bladder cancer.

    Clinical/Scientific Implications
    There is a large move toward organ preserving treatment in all oncologic treatment. This is also true for bladder cancer. Although there have been many recent advances giving patients alternatives to urostomy(diversion of the urine to an external pouch), retention of the bladder can be good for many patients in terms of quality of life. Since OS and DSS is comparable to historic data and there was little long term toxicity from bladder conservation therapy, this is an acceptable alternative to cystectomy in motivated patients.

  • OncoLink I wish u knew...

    Common misconceptions and myths about pain medication and pain control. Read more.

    Cancer Types
    Bone Cancer
    Brain Tumors
    Breast Cancer
    Carcinoid Tumors
    Endocrine System Cancers
    Gastrointestinal Cancers
    Gynecologic Cancers
    Head and Neck Cancers
    Leukemia
    Lung Cancers
    Lymphomas
    Myelomas
    Pediatric Cancers
    Penile Cancer
    Prostate Cancer
    Sarcomas
    Skin Cancers
    Testicular Cancer
    Thyroid Cancer
    Urinary Tract Cancers
    OncoLink Vet

    Cancer Treatment
    Biologic Therapy
    Bone Marrow Transplants
    Chemotherapy

    Clinical Trials
    Complementary Medicine
    Gene Therapy
    General Treatment Concerns
    Hormone Therapy
    PDT Center
    Proton Therapy
    Radiation Oncology
    Surgical Oncology
    Targeted Therapies
    Vaccine Therapies

    Cancer Support
    Caregivers
    Hospice Care and Bereavement
    Nutrition and Cancer
    Sexuality & Fertility
    Side Effects
    Support
    Survivorship
    Exercise and Cancer

    Cancer Resources
    Cancer News
    OncoLink University
    Nurses' Notes
    Conferences
    Newly Diagnosed Patients
    Causes and Prevention
    Legal and Financial Information for Patients
    LGBT Resources
    NCI Resources
    Global Resources
    Cancer Resource List
    Resources for Young Adults

    OncoLink Media Library
    OncoLink TV
    Book, Music and Video Reviews


    Ask the Experts
    Brown Bag Chat
    Tracy's Corner

    About OncoLink
    About OncoLink
    Giving to OncoLink
    Contact Information
    Usage Policy
    Editorial Board
    How to Partner with OncoLink
    Link to OncoLink
    Mission Statement

    OncoLink Cancer Resources RSS What's New RSS